Design, synthesis and structure-activity relationships of a novel class of sulfonylpyridine inhibitors of Interleukin-2 inducible T-cell kinase (ITK).
Trani, G., Barker, J.J., Bromidge, S.M., Brookfield, F.A., Burch, J.D., Chen, Y., Eigenbrot, C., Heifetz, A., Ismaili, M.H., Johnson, A., Krulle, T.M., MacKinnon, C.H., Maghames, R., McEwan, P.A., Montalbetti, C.A., Ortwine, D.F., Perez-Fuertes, Y., Vaidya, D.G., Wang, X., Zarrin, A.A., Pei, Z.(2014) Bioorg Med Chem Lett 24: 5818-5823
- PubMed: 25455497 
- DOI: https://doi.org/10.1016/j.bmcl.2014.10.020
- Primary Citation of Related Structures:  
4QD6 - PubMed Abstract: 
Starting from benzylpyrimidine 2, molecular modeling and X-ray crystallography were used to design highly potent inhibitors of Interleukin-2 inducible T-cell kinase (ITK). Sulfonylpyridine 4i showed sub-nanomolar affinity against ITK, was selective versus Lck and its activity in the Jurkat cell-based assay was greatly improved over 2.
Organizational Affiliation: 
Discovery Chemistry, Evotec UK Ltd, 114 Innovation Drive, Milton Park, Abingdon, OX14 4RZ, UK. Electronic address: Giancarlo.Trani@evotec.com.